Table 2.
Number (%) of subjects by demographic characteristics at baseline, CDC Anthrax Vaccine Adsorbed Human Clinical Trial, 2002-2005.
| Treatment groups | |||||||
|---|---|---|---|---|---|---|---|
| 8SQ-An = 259 | 8IM-An = 262 | 7IM-An = 256 | 5IM-An = 258 | 4IM-An = 267 | 8IM-Pn = 127 | 8SQ-Pn = 133 | |
| Age group* | |||||||
| <30 | 77 (30) | 63 (24) | 75 (29) | 77 (30) | 72 (27) | 35 (28) | 40 (30) |
| 30–39 | 42 (16) | 57 (22) | 77 (30) | 65 (25) | 60 (22) | 29 (23) | 31 (23) |
| 40–49 | 91 (35) | 87 (33) | 54 (21) | 64 (25) | 90 (34) | 35 (28) | 38 (29) |
| ≥50 | 49 (19) | 55 (21) | 50 (20) | 52 (20) | 45 (17) | 28 (22) | 24 (18) |
| Race | |||||||
| Black | 47 (18) | 48 (18) | 49 (19) | 62 (24) | 59 (22) | 28 (22) | 31 (23) |
| White | 199 (77) | 197 (75) | 194 (76) | 183 (71) | 200 (75) | 90 (71) | 95 (71) |
| Other | 13 (5) | 17 (6) | 13 (5) | 13 (5) | 8 (3) | 9 (7) | 7 (5) |
| Sex | |||||||
| Female | 134 (52) | 135 (52) | 132 (52) | 131 (51) | 135 (51) | 64 (50) | 68 (51) |
| Male | 125 (48) | 127 (48) | 124 (48) | 127 (49) | 132 (49) | 63 (50) | 65 (49) |
| Smoking status | |||||||
| Non smoker | 153 (59) | 163 (62) | 160 (63) | 158 (61) | 177 (66) | 84 (66) | 84 (63) |
| Smoker | 106 (41) | 99 (38) | 96 (38) | 100 (39) | 89 (33) | 43 (34) | 49 (37) |
| BMI group | |||||||
| Underweight | 0 (0) | 4 (2) | 5 (2) | 2 (1) | 5 (2) | 3 (2) | 1 (1) |
| Normal | 99 (38) | 79 (30) | 90 (35) | 88 (34) | 86 (32) | 37 (29) | 54 (41) |
| Overweight | 84 (32) | 105 (40) | 82 (32) | 91 (35) | 90 (34) | 51 (40) | 42 (32) |
| Obese | 76 (29) | 74 (28) | 79 (31) | 77 (30) | 86 (32) | 36 (28) | 36 (27) |
Note: There was one person with unknown smoking status in treatment group 4IM-A.
*
Chi-square p-value for test of homogeneity across treatment groups: 0.04; p-values for all other covariates were non-significant.